Prostate cancer (PC) is the most common malignancy and third most common cause of cancer-related death among men in Europe. Although most PCs grow slowly, 2025% of the patients believed to have organ-confined disease will experience biochemical recurrence already during 5-years of follow-up. The standard treatment against advanced PC is androgen deprivation (ADT). Unfortunately, androgen deprivation treatment eventually fails leading to the emergence of castration resistant PC (CRPC) that is lethal. However, also CRPCs are dependent on androgens. Owing to this understanding, several drugs have recently emerged for the treatment of CRPC including enzalutamide and abiraterone, but approximately 2040% of patients have no response to these agents. One explanation to this could be the expression of constitutively active androgen receptor splice variants (AR-Vs). The aim of our project is to interrogate all possible AR aberrations in PC and CRPC. We have set up two NGS panels using Agilents SureSelect Target Enrichment system allowing detection of all AR transcript variants as well as AR mutations, copy number variations and rearrangements. The assays have been validated with our existing whole-genome sequencing and RNA-seq data. We are now running samples representing hormone-naïve PC, neoadjuvant ADT treated PCs as well as CRPCs. The data will be presented in the meeting.
Presenting author: Heini M.L. Kallio, BioMediTech, University of Tampere, Lääkärinkatu 1, 33520 Tampere, Finland. Email: email@example.com.